GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigene AG (XTER:MDG1) » Definitions » Valuation Rank

Medigene AG (XTER:MDG1) Valuation Rank


View and export this data going back to 2000. Start your Free Trial

What is Medigene AG Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Medigene AG Valuation Rank Related Terms

Thank you for viewing the detailed overview of Medigene AG's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Medigene AG (XTER:MDG1) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigene AG (XTER:MDG1) » Definitions » Valuation Rank
Comparable Companies
XTER:T5O XTER:HPHA OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX ALNY OCSE:GMAB BGNE BMRN INCY TECH UTHR RPRX
Traded in Other Exchanges
0QGJ:UK MDG1:Austria
Address
Lochhamer Strasse 11, Martinsried, Planegg, BY, DEU, 82152
Website
https://www.medigene.com
Medigene AG is an immuno-oncology biotechnology company. focused on developing differentiated T Cell Receptor engineered T cell (TCR-T) therapies for the treatment of multiple solid tumor indications with a high unmet medical need. The operating segments of the organization are Immunotherapies and Other products. Immunotherapies consist of T-cell receptor-based adoptive T-cell therapy and DC vaccines. The group operates in the United States, Germany, and Asia, of which the majority of the revenue is derived from operations in Germany.